BIIB STOCK ALERT: Zhang Investor Law Announces Securities Class Action Lawsuit Against Biogen Inc. - BIIB

Bank of America Corp

Change company Symbol lookup

Select an option...

BAC Bank of America Corp

GPHBF Graphene 3D Lab Inc(British Columbia)

ITRI Itron Inc

LTTTX MFS Lifetime 2025 Fund Class R3

HLI Houlihan Lokey Inc

KICK Master Glazier's Karate International Inc

VIRT Virtu Financial Inc

FB Facebook Inc

ED Consolidated Edison Inc

CLS Celestica Inc

Financials : Banks | Large Cap Value

Company profile

Bank of America Corporation is a bank holding company and a financial holding company. The Company is a financial institution, serving individual consumers and others with a range of banking, investing, asset management and other financial and risk management products and services. The Company, through its banking and various non-bank subsidiaries, throughout the United States and in international markets, provides a range of banking and non-bank financial services and products through four business segments: Consumer Banking, which comprises Deposits and Consumer Lending; Global Wealth & Investment Management, which consists of two primary businesses: Merrill Lynch Global Wealth Management and U.S. Trust, Bank of America Private Wealth Management; Global Banking, which provides a range of lending-related products and services; Global Markets, which offers sales and trading services, and All Other, which consists of equity investments, residual expense allocations and other.

BIIB STOCK ALERT: Zhang Investor Law Announces Securities Class Action Lawsuit Against Biogen Inc. - BIIB

10:16 am ET November 19, 2020 (Globe Newswire) Print

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Biogen Inc. (NASDAQ: BIIB) between October 22, 2019 and November 6, 2020, inclusive (the "Class Period").

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=biogen-inc&id=2484 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

å¦?æ??æ?¨æ?³å? å?¥è¿?ä¸ªé??ä½"è¯?è®¼æ¡?ï¼?è¯·å?¨è¿?é??æäº¤æ?¨ç??ä¿¡æ¯ã??http://zhanginvestorlaw.com/join-action-form/?slug=biogen-inc&id=2484.

If you wish to serve as lead plaintiff, you must move the Court before the January 12, 2021 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: the larger dataset did not provide necessary data regarding aducanumab's effectiveness; the EMERGE study did not and would not provide necessary data regarding aducanumab's effectiveness; the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; the data provided by the Company to the FDA's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.

99 Wall Street, Suite 232

New York, New York 10005

info@zhanginvestorlaw.com

tel: (800) 991-3756

https://ml.globenewswire.com/media/2e68a1c2-58ac-4be0-98d5-8b26afb52403/small/zahng-investor-law-png.png